Literature DB >> 12694821

Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.

Daphne A Haas-Kogan1, Patrick S Swift, Michael Selch, Gerald M Haase, Robert C Seeger, Robert B Gerbing, Daniel O Stram, Katherine K Matthay.   

Abstract

PURPOSE: To assess the effect of local radiation administered to primary disease sites in children with high-risk neuroblastoma.
MATERIALS AND METHODS: A total of 539 eligible patients were entered on protocol CCG-3891, consisting of chemotherapy, primary surgery, and 10 Gy of external beam radiation therapy (EBRT) to gross residual disease, followed by randomized assignment to continuation chemotherapy (CC) or autologous bone marrow transplantation (ABMT). ABMT patients received total body irradiation (TBI).
RESULTS: Estimated event-free survival and overall survival at 5 years were 25% +/- 2% and 35% +/- 2%, respectively. Estimated 5-year locoregional recurrence rates were 51% +/- 5% and 33% +/- 7% for CC and ABMT patients (p = 0.004). For patients who received 10 Gy of EBRT to the primary, the addition of 10 Gy of TBI and ABMT decreased local recurrence compared with CC (22% +/- 12% and 52% +/- 8%, p = 0.022). EBRT did not increase acute toxicity, except for increased total parenteral nutrition administration.
CONCLUSIONS: In combination with EBRT to the primary tumor site, the addition of 10 Gy of TBI as a component of high-dose chemotherapy with ABMT improved local control compared with CC without TBI. Results suggest a dose-response relationship for local EBRT. Short-term toxicity of local EBRT is limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694821     DOI: 10.1016/s0360-3016(02)04506-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  39 in total

1.  Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.

Authors:  Steve E Braunstein; Wendy B London; Susan G Kreissman; Judith G Villablanca; Andrew M Davidoff; Kenneth DeSantes; Robert P Castleberry; Kevin Murray; Lisa Diller; Katherine Matthay; Susan L Cohn; Barry Shulkin; Daniel von Allmen; Marguerite T Parisi; Collin Van Ryn; Julie R Park; Michael P La Quaglia; Daphne A Haas-Kogan
Journal:  Pediatr Blood Cancer       Date:  2019-04-09       Impact factor: 3.167

2.  Osteochondroma in long-term survivors of high-risk neuroblastoma.

Authors:  Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

3.  Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

Authors:  Brian H Kushner; Nai-Kong V Cheung; Christopher A Barker; Kim Kramer; Shakeel Modak; Karima Yataghene; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-08       Impact factor: 7.038

4.  Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

Authors:  Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Michael P LaQuaglia; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-02-11       Impact factor: 7.038

5.  Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008.

Authors:  Vikram Jairam; Kenneth B Roberts; James B Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-27       Impact factor: 7.038

6.  Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

Authors:  Jared R Robbins; Matthew J Krasin; Atmaram S Pai Panandiker; Amy Watkins; Jianrong Wu; Victor M Santana; Wayne L Furman; Andrew M Davidoff; Lisa M McGregor
Journal:  J Pediatr Surg       Date:  2010-04       Impact factor: 2.545

Review 7.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Frank Berthold
Journal:  Cochrane Database Syst Rev       Date:  2017-08-25

8.  Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.

Authors:  Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-27       Impact factor: 7.038

9.  Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Authors:  Dana L Casey; Ken L Pitter; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-09       Impact factor: 7.038

10.  Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.

Authors:  Brian H Kushner; Kim Kramer; Shakeel Modak; Li-Xuan Qin; Karima Yataghena; Suresh C Jhanwar; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.